Cargando…

Letter to the Editor in Response to: Hypersensitivity Reaction to Ustekinumab in Pediatric and Young Adult Inflammatory Bowel Disease Patients: A Case Series

Detalles Bibliográficos
Autores principales:	Samalik, Joann, Adler, Jeremy, Singer, Andrew A. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins, Inc. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187828/ https://www.ncbi.nlm.nih.gov/pubmed/37200724 http://dx.doi.org/10.1097/PG9.0000000000000293

Ejemplares similares

Hypersensitivity Reaction to Ustekinumab in Pediatric and Young Adult Inflammatory Bowel Disease Patients: A Case Series
por: Sunny, Julee, et al.
Publicado: (2022)

Letter to the Editor: Metal hypersensitivity reactions in the context of Essure™
por: Markel, Kory, et al.
Publicado: (2018)

Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease
por: Gara, Sirisha K, et al.
Publicado: (2023)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Letter to the editor: Triclosan in patients with inflammatory bowel disease
por: Peña-Cardelles, Juan Francisco
Publicado: (2022)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Late Reaction to Ustekinumab Infusion
por: Morais, Marina Resener, et al.
Publicado: (2013)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease
por: Roblin, Xavier, et al.
Publicado: (2023)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Treatment of Inflammatory Bowel Disease and Pediatric Onset Multiple Sclerosis With Ocrelizumab and Ustekinumab in a JC-virus Positive Adolescent
por: Lambert-Jenkins, Kristin, et al.
Publicado: (2022)

Letter to the Editor: Two Major Phenotypes of Sulfite Hypersensitivity: Asthma and Urticaria
por: Ban, Ga-Young, et al.
Publicado: (2014)

Interstitial Granulomatous Drug Reaction to Ustekinumab
por: Walker, A., et al.
Publicado: (2022)

Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease
por: Kono, Masashi, et al.
Publicado: (2019)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Effects of Golimumab and Ustekinumab on Circulating Dendritic Cell Migratory Capacity in Inflammatory Bowel Disease
por: Soleto, Irene, et al.
Publicado: (2023)

Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases
por: Viola, Anna, et al.
Publicado: (2021)

Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

Comprehensive Review of Ustekinumab Utilization in Inflammatory Bowel Diseases: Insights from the ClinicalTrials.gov Registry
por: Alorfi, Nasser M, et al.
Publicado: (2023)

“Role of exercise in preventing and restoring gut dysbiosis in patients with inflammatory bowel disease”: A letter to the editor
por: Mc Gettigan, Neasa, et al.
Publicado: (2022)

Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases
por: Ceuleers, Hannah, et al.
Publicado: (2016)

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
por: Sandborn, William J, et al.
Publicado: (2020)

Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
por: Thunberg, Joel, et al.
Publicado: (2022)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Letter to the Editor [Letter]
por: Félix, Sylvie
Publicado: (2021)

Letter to the Editor: Regarding “The Role of Obesity in Pediatric Orthopedics”
por: Rehm, Andreas, et al.
Publicado: (2020)

Reply to Letter to Editor: Choroidal Thickness in Pediatric Population
por: Heravian Shandiz, Javad, et al.
Publicado: (2021)

Assessing the Use of Ustekinumab in a Pediatric Patient With Harlequin Ichthyosis
por: Almuhanna, Nouf, et al.
Publicado: (2023)

Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study
por: Mitrova, Katarina, et al.
Publicado: (2021)

Corrigendum to: Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
Publicado: (2021)

How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data
por: Gutiérrez, Ana, et al.
Publicado: (2021)

Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs: An Update
por: Sánchez-Borges, Mario, et al.
Publicado: (2010)

Letter to the Editor
Publicado: (1997)

Letter to the Editor
por: Wölner-Hanssen, Pål
Publicado: (1996)

Letter to The Editor
por: Goldring, J. R.
Publicado: (1989)

Letters to the Editor
Publicado: (1998)

Letter to the Editor
por: Pouwer, Frans
Publicado: (2008)

Letters to the Editor
por: Levine, Elliott M.
Publicado: (2001)

Letter to the editor
por: Kanna, Balavenkatesh, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_56cvabkes1dov2kk0d0ooqoljv